Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited will hold its 2025 annual general meeting (AGM) on 29 May 2026 at 10:00 a.m. in Guangzhou. The H-share register will be closed from 23–29 May 2026; investors must lodge share transfers by 4:30 p.m. on 22 May 2026 to qualify for attendance and voting.

Key agenda items:

1. Board Transition • Shareholders will vote on ten director positions for the 10th Board (three-year term). – Executive Director re-elections: Chen Jiehui, Cheng Hongjin, Tang Heping. – New Executive Directors: Liu Lan, Yuan Cheng. – New Non-executive Director: Huang Jiyuan. – Independent Non-executive Director (INED) re-elections: Wong Lung Tak Patrick, Sun Baoqing. – New INEDs: Wu Xiangneng, Yang Yinbao. • Chairman Li Xiaojun, Executive Director Li Hong and INEDs Chen Yajin and Huang Min will retire and will not seek re-election.

2. Major Financing Mandate • Management requests shareholder approval to secure omnibus credit facilities of up to RMB 64.12 billion and HKD 0.10 billion from financial institutions. • The facilities may cover working-capital loans, bank acceptances, letters of credit and guarantees, effective until the next AGM.

3. Auditor Re-appointment • WUYIGE Certified Public Accountants LLP is nominated to continue as statutory and internal control auditor for FY 2026. • Proposed audit fee: RMB 3.13 million; internal control audit fee: RMB 0.40 million.

4. Director Remuneration • Individual remuneration packages for outgoing and incoming directors for FY 2026 will be submitted for approval, calculated pro-rata to actual tenure.

Shareholders unable to attend may lodge proxy forms with Computershare Hong Kong Investor Services by 28 May 2026 (24 hours before the meeting). All resolutions will be decided by poll.